{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T22:07:05Z","timestamp":1786226825110,"version":"build-2736575974"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The U.S. Food and Drug Administration (FDA) recommends concurrent development of targeted therapies with an associated companion diagnostic (CDx) as the optimal approach to provide patient access to novel, safe, and effective treatments. However, CDx validation often relies on clinical samples from pivotal clinical trials for the drug, which can be challenging, particularly when there is limited sample availability. A review of Summary of Safety and Effectiveness Data (SSED) documents for CDx approved for non-small cell lung cancer (NSCLC) revealed that CDx for rare biomarkers often use alternative samples for validation. While the practice of using alternative samples for validation occurs, it is not always clear when these flexibilities are considered or how alternative samples should be used for validation. To address this, we propose the FDA establish guidance for the use of alternative sample sources for CDx validation, especially for rare biomarkers, to ensure timely and effective patient access to targeted therapies.<\/jats:p>","DOI":"10.1007\/s43441-025-00799-7","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T13:38:07Z","timestamp":1747316287000},"page":"676-679","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Companion Diagnostic FDA Review Flexibilities: An Assessment of CDx for NSCLC to Support Aligned Approaches for Validation"],"prefix":"10.1007","volume":"59","author":[{"given":"Hillary S.","family":"Andrews","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernat","family":"Navarro-Serer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff D.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"799_CR1","unstructured":"U.S. Food and Drug Administration. In Vitro Companion Diagnostic Devices Guidance for Industry and Food and Drug Administration Staff. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/in-vitro-companion-diagnostic-devices"},{"key":"799_CR2","unstructured":"U.S. Food and Drug Administration. Principles for Codevelopment of an In Vitro Companion Diagnostic Device with a Therapeutic Product Draft Guidance for Industry and Food and Drug Administration Staff. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/principles-codevelopment-in-vitro-companion-diagnostic-device-therapeutic-product"},{"key":"799_CR3","doi-asserted-by":"crossref","unstructured":"J\u00f8rgensen JT. Missing Companion Diagnostic for US Food and Drug Administration-Approved Hematological and Oncological Drugs. JCO Precis Oncol. 2022;6:e2200100. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35709402\/","DOI":"10.1200\/PO.22.00100"},{"key":"799_CR4","unstructured":"Bousnina I, Doyle M, Huston M, Kalamegham R, Katrivanos E, Koontz L. Expedited development of diagnostics for therapies targeting rare biomarkers or indications White Paper [Internet]. 2022. Available from: https:\/\/friendsofcancerresearch.org\/wp-content\/uploads\/Dx_For_Rare_Biomarkers_White_Paper.pdf"},{"key":"799_CR5","doi-asserted-by":"publisher","first-page":"332","DOI":"10.20517\/CDR.2022.105","volume":"6","author":"M Muminovic","year":"2023","unstructured":"Muminovic M, Uribe CRC, Alvarez-Pinzon A, Shan K, Raez LE. Importance of ROS1 gene fusions in non-small cell lung cancer. Cancer Drug Resist. 2023;6:332. https:\/\/doi.org\/10.20517\/CDR.2022.105.","journal-title":"Cancer Drug Resist"},{"key":"799_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41698-024-00552-7","volume":"8","author":"D Planchard","year":"2024","unstructured":"Planchard D, Sanborn RE, NM V, Vaishnavi A, Smit EF. BRAFV600E-mutant metastatic NSCLC: disease overview and treatment landscape. Npj Precision Oncol 2024. 2024;8:1. https:\/\/doi.org\/10.1038\/s41698-024-00552-7.","journal-title":"Npj Precision Oncol 2024"},{"key":"799_CR7","unstructured":"Food US, Administration D. CDRH. Summary of Safety and Effectiveness Data (SSED) for P160045 [Internet]. 2017. Available from: https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf16\/P160045B.pdf"},{"key":"799_CR8","unstructured":"Food US, Administration D. CDRH. Summary of Safety and Effectiveness Data (SSED) for P170019 [Internet]. 2017. Available from: https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf17\/P170019B.pdf"},{"key":"799_CR9","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1056\/NEJMOA1006448","volume":"363","author":"EL Kwak","year":"2010","unstructured":"Kwak EL, Bang Y-J, Camidge DR, Shaw AT, Solomon B, Maki RG. Anaplastic lymphoma kinase Inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693\u2013703. https:\/\/doi.org\/10.1056\/NEJMOA1006448.","journal-title":"N Engl J Med"},{"key":"799_CR10","doi-asserted-by":"publisher","unstructured":"Lim TKH, Skoulidis F, Kerr KM, Ahn MJ, Kapp S JR. F.A. KRAS G12C in advanced NSCLC: prevalence, co-mutations, and testing. Lung Cancer 2023;184. https:\/\/doi.org\/10.1016\/J.LUNGCAN.2023.107293","DOI":"10.1016\/J.LUNGCAN.2023.107293"},{"key":"799_CR11","unstructured":"Food US, Administration D. CDRH. Summary of Safety and Effectiveness Data (SSED) for P210040 [Internet]. 2022. Available from: https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf21\/P210040B.pdf"},{"key":"799_CR12","unstructured":"Food US, Administration D. CDRH. Summary of Safety and Effectiveness Data (SSED) for P200006 [Internet]. 2020. Available from: https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf20\/P200006B.pdf"},{"key":"799_CR13","doi-asserted-by":"publisher","first-page":"78985","DOI":"10.18632\/ONCOTARGET.12587","volume":"7","author":"Y-L Zhang","year":"2016","unstructured":"Zhang Y-L, Yuan J-Q, Wang K-F, Fu X-H, Han X-R, Threapleton D. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7:78985\u201393. https:\/\/doi.org\/10.18632\/ONCOTARGET.12587.","journal-title":"Oncotarget"},{"key":"799_CR14","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/J.JTHO.2016.04.014","volume":"11","author":"H Yu","year":"2016","unstructured":"Yu H, Boyle TA, Zhou C, Rimm DL, Hirsch FR. PD-L1 expression in lung Cancer. J Thorac Oncol. 2016;11:964. https:\/\/doi.org\/10.1016\/J.JTHO.2016.04.014.","journal-title":"J Thorac Oncol"},{"key":"799_CR15","unstructured":"Food US, Administration D. CDRH. Summary of Safety and Effectiveness Data (SSED) for P200010 [Internet]. 2020. Available from: https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf20\/P200010B.pdf"},{"key":"799_CR16","unstructured":"Andrews H, D\u2019Apote L, Das B, Dickey J, Doyle M, Freaney J et al. Innovative validation and regulatory processes for companion diagnostic tests for rare biomarkers or indications White Paper 2025. https:\/\/friendsofcancerresearch.org\/wp-content\/uploads\/Innovative-Validation-and-Regulatory-Processes-for-Companion-Diagnostic-Tests-for-Rare-Biomarkers-or-Indications.pdf"}],"container-title":["Therapeutic Innovation &amp; Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-025-00799-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-025-00799-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-025-00799-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T18:39:07Z","timestamp":1750444747000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43441-025-00799-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["799"],"URL":"https:\/\/doi.org\/10.1007\/s43441-025-00799-7","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]},"assertion":[{"value":"6 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}